A New Approach to Treating Autoimmune Skin Diseases
Regranion, LLC is a clinical-stage pharmaceutical company delivering breakthrough solutions for autoimmune skin diseases by targeting a conserved pathway that contributes to hyperinflammation.
RGRN-305, our lead product, is an orally delivered potent small molecule inhibitor of heat shock protein 90 (HSP90) that has demonstrated activity as a broad-spectrum anti-inflammatory molecule and clinical safety and efficacy in patients with autoimmune skin disease.
Unique mechanism of action confers clear market differentiation
RGRN-305 is a broad-spectrum anti-inflammatory molecule that targets multiple inflammatory mediators of dermal diseases, rather than an individual cytokine or chemokine
Commercial opportunity in numerous indications with high unmet clinical need
RGRN-305 downregulates key inflammatory mediators of psoriasis, atopic dermatitis, bullous pemphigoid, and hidradenitis suppurativa
Clinically proven safety and efficacy profile
No ocular, CNS, or cardiac toxicity and no consistent changes in hematology or biochemistry parameters in clinical trials; efficacy in resolving plaque psoriasis symptoms in a Phase 1b clinical trial
RGRN-305 has proven results in
moderate to severe plaque psoriasis
Before Treatment
After Treatment
Technology Overview and Therapeutic Approach
Product Pipeline
RGRN-305 is in development for multiple indications of autoimmune skin diseases including psoriasis, atopic dermatitis, hidradenitis suppurativa, and bullous pemphigoid.